share_log

AbbVie Completes Acquisition of Landos Biopharma

AbbVie Completes Acquisition of Landos Biopharma

艾伯維完成對蘭多斯生物製藥的收購
艾伯維公司 ·  05/23 12:00

- Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)

- 在 AbbVie 的產品線中增加了同類首創的研究資產 NX-13,有可能提供一種治療潰瘍性結腸炎 (UC) 和克羅恩氏病 (CD) 的新方法

NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.

伊利諾伊州北芝加哥,2024 年 5 月 23 日/PRNewswire/— 艾伯維(紐約證券交易所代碼:ABBV)今天宣佈,它已完成對蘭多斯生物製藥公司(納斯達克股票代碼:LABP)的收購。收購完成後,蘭多斯現在是艾伯維的一部分。

Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowel disease (IBD) pathogenesis. With a dual mechanism of action that is anti-inflammatory and facilitates epithelial repair, NX-13 has the potential to offer a novel approach to the treatment of UC and CD.

蘭多斯的主要研究資產是 NX-13,這是同類首創的口服 NLRX1 激動劑(NOD樣受體家族的一員),目前處於治療中度至重度UC的第二階段(NEXUS研究;NCT05785715)。NLRX1 調節免疫代謝和炎症,其激活可以解決炎症性腸病 (IBD) 的發病機制。NX-13 具有抗炎和促進上皮修復的雙重作用機制,有可能爲UC和CD的治療提供一種新的方法。

"Many people living with IBD are not able to achieve or maintain remission and continue to experience debilitating symptoms," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. "The addition of NX-13 complements our portfolio in immunology and strengthens our collective efforts to transform standard of care. I want to commend the Landos team for their efforts in advancing our shared mission of developing medicines for those who need it most."

艾伯維副總裁兼免疫學臨床開發全球負責人科裏·華萊士醫學博士說:“許多IBD患者無法緩解或維持緩解,並繼續出現使人衰弱的症狀。”“NX-13 的加入補充了我們在免疫學領域的產品組合,並加強了我們改變護理標準的集體努力。我要讚揚蘭多斯團隊爲推進我們爲最需要的人開發藥物的共同使命所做的努力。”

For additional background on the acquisition, please read the announcement press release here.

有關此次收購的更多背景信息,請閱讀公告新聞稿 這裏

Financial Terms
AbbVie has acquired Landos at a price of $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone. Landos' common stock will cease to trade on the NASDAQ stock exchange prior to market open on May 24, 2024.

財務條款
艾伯維已以每股20.42美元的價格收購了Landos,外加每股一項不可交易的或有價值權利,價值最高爲每股11.14美元,但須視臨床開發里程碑的實現而定。蘭多斯的普通股將在2024年5月24日開市前停止在納斯達克證券交易所交易。

About the NEXUS Study
NEXUS is a Phase 2 proof-of-concept clinical trial evaluating NX-13 in patients with moderate to severe UC. NEXUS is a randomized, multicenter, double-blind, placebo-controlled, multiple dose, 12-week induction study evaluating 80 patients with moderate to severe UC with a long-term extension (LTE) period. All subjects will be randomized to receive either 250 mg or 750 mg immediate release NX-13, or placebo. The primary objective of the trial will be to evaluate clinical efficacy, safety and pharmacokinetics of oral NX-13 versus placebo (NCT05785715 ClinicalTrials.gov).

關於 NEXUS 研究
NEXUS 是一項 2 期概念驗證臨床試驗,評估中度至重度 UC 患者的 NX-13。NEXUS是一項隨機、多中心、雙盲、安慰劑對照、多劑量、爲期12周的誘導研究,評估了80名長期延期(LTE)的中度至重度UC患者。所有受試者將被隨機分配 250 mg 或 750 mg 即時釋放 NX-13 或安慰劑。該試驗的主要目標將是評估口服 NX-13 對比安慰劑(NCT05785715 ClinicalTrials.gov)的臨床療效、安全性和藥代動力學。

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

關於 AbbVie
艾伯維的使命是發現和提供創新的藥物和解決方案,以解決當今嚴重的健康問題並應對未來的醫療挑戰。我們努力在幾個關鍵治療領域(免疫學、腫瘤學、神經科學和眼部護理)以及我們的Allergan Aesthetics產品組合中的產品和服務,對人們的生活產生顯著影響。有關 AbbVie 的更多信息,請訪問我們 www.abbvie.com。繼續關注 @abbvie 領英, FacebookInstagramX(前身爲 Twitter),以及 YouTube

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. Forward looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward looking statements, and AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

前瞻性陳述
就1995年《私人證券訴訟改革法》而言,本新聞稿中的一些陳述是前瞻性陳述,或可能被視爲前瞻性陳述。“相信”、“期望”、“預期”、“項目” 等詞以及未來或條件動詞的類似表達和用法通常指前瞻性陳述。艾伯維警告說,這些前瞻性陳述存在風險和不確定性,可能導致實際結果與前瞻性陳述中表達或暗示的結果存在重大差異。此類風險和不確定性包括但不限於對知識產權的挑戰、來自其他產品的競爭、研發過程中固有的困難、不利訴訟或政府行動,以及適用於我們行業的法律法規的變化。有關可能影響艾伯維運營的經濟、競爭、政府、技術和其他因素的更多信息,見艾伯維2023年10-K表年度報告的第1A項 “風險因素”,該報告已提交給美國證券交易委員會,並由其隨後的10-Q表季度報告進行了更新。前瞻性陳述僅代表其發表之日。提醒讀者不要過分依賴前瞻性陳述,除非法律要求,否則艾伯維沒有義務公開發布因後續事件或事態發展而對前瞻性陳述的任何修訂。

AbbVie logo

SOURCE AbbVie

來源 AbbVie

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論